Get the Stockscreener App
17.01
0.00%
0.00
After Hours:
16.89
-0.12
-0.71%
Theravance Biopharma Inc stock is traded at $17.01, with a volume of 407.23K.
It is up +0.00% in the last 24 hours and up +0.89% over the past month.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
See More
Previous Close:
$17.01
Open:
$16.99
24h Volume:
407.23K
Relative Volume:
0.65
Market Cap:
$883.14M
Revenue:
$109.78M
Net Income/Loss:
$114.54M
P/E Ratio:
7.7157
EPS:
2.2046
Net Cash Flow:
$268.74M
1W Performance:
+0.53%
1M Performance:
+0.89%
6M Performance:
-10.76%
1Y Performance:
+22.29%
1-Day Range:
$16.97
$17.03
1-Week Range:
$16.93
$17.03
52-Week Range:
$13.08
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
17.01 | 880.02M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-04-26 | Downgrade | B. Riley Securities | Buy → Neutral |
| Dec-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan
Madison Avenue Partners, LP Trims Theravance Biopharma Inc (TBPH) Stake in Portfolio Rebalancing Move - GuruFocus
Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH - TradingView
Theravance Biopharma Inc (NASDAQ: TBPH) Share Price, TBPH Stock News, TBPH Share Price & Updates - Kalkine
Theravance (TBPH) Update: Rises 0.18% to $16.98 on the Day; Price Setup: Traders Can Monitor the $16.13-$17.83 RangeSupport Level Bounce - vinanet.vn
Theravance Biopharma (TBPH) Edges Higher to $16.97, Trapped Between Key Support and ResistanceFactor Valuation - vinanet.vn
Theravance Biopharma Deal Faces Investor Probe - stl.news
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders - The AI Journal
Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma (TBPH) Holds Steady at $16.97 as Traders Eye Range-Bound MoveCovered Call Trade - vinanet.vn
Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A - Stock Titan
Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake - Stock Titan
(TBPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Theravance Biopharma (TBPH) Stock Caught Between Fading Gains And Royalty Doubts - Sahm
Theravance Biopharma Announces Q2 2026 Financial Results with $10.8M Net Loss Amid Restructuring - Kalkine Media
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView
Theravance Biopharma (NASDAQ: TBPH) details $17 cash payout and ampreloxetine CVRs in Zymeworks deal - Stock Titan
Theravance Biopharma, Inc. 2026: Revenue $20.73M, EPS ($0.11) — 10-Q Summary - TradingView
Theravance Biopharma (TBPH) agrees $17 cash sale to Zymeworks plus CVRs - Stock Titan
Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH - MarketBeat
Israel Business NewsGlobes - Globes - Israel Business News
Theravance Biopharma earnings missed by $0.17, revenue fell short of estimates - Investing.com Canada
Theravance Biopharma Releases Q2 2026 Financial Results - AlphaStreet
Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY - Bitget
Theravance Biopharma Q2 Results: Adj. EPS beats by 260% - scanx.trade
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations - MarketBeat
Form 8K Theravance Biopharma Inc For: 10 August By Investing.com - Investing.com Australia
TBPH Looks 29.8% Undervalued on GF Value™ Amid Acquisition News - GuruFocus
Theravance Biopharma Swings to Net Loss in Q2, Revenue Falls - marketscreener.com
Earnings Flash (TBPH) Theravance Biopharma Posts Q2 Net Loss $0.11 a Share, vs. FactSet Est of $0.07 EPS - marketscreener.com
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q2 Revenue $20.7M, vs. FactSet Est of $22.5M - marketscreener.com
Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash - TradingView
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates - TradingView
Theravance Bio: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Theravance Biopharma Q2 Operating Income USD -8.277 Million - TradingView
THERAVANCE BIOPHARMA Q2 OPERATING INCOME USD -8.277 MILLION - Moomoo
Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Strong Revenue Growth and High ROE Offer Intriguing Investment Prospects - DirectorsTalk Interviews
Theravance Biopharma (TBPH) Expected to Announce Earnings on Tuesday - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
(TBPH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Theravance Biopharma (TBPH) Q1 2026 Earnings: 79.48% EPS Surprise Highlights Cost Discipline Amid Limited Top-Line VisibilityPre-Announcement Alert - vinanet.vn
Swiss National Bank Invests $1.22 Million in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Evaluating a 4.85% Potential Upside Amidst Biotech Ambitions - DirectorsTalk Interviews
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Theravance Biopharma (TBPH) Holds Steady Near Support as Trading Volume Remains MutedMomentum Surge Alerts - dars.gov.et
TBPH Q2'26 Earnings: revenue estimate is 22.49M USD - TradingView
ETFs Investing in Theravance Biopharma Inc Stocks - TradingView
Theravance Biopharma Inc (TBPH) Cash Flow - TradingKey
TBPH|Theravance Biopharma Inc|Price:16.865|Chg%:+0.005 - TradingKey
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Theravance Biopharma Inc Stock (TBPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Samaha Eli | 10% Owner |
Jul 01 '26 |
Sale |
17.00 |
37,799 |
642,628 |
9,174,453 |
| Samaha Eli | 10% Owner |
Jun 30 '26 |
Sale |
17.13 |
25,027 |
428,788 |
9,212,252 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jun 15 '26 |
Sale |
16.39 |
13,314 |
218,167 |
232,457 |
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):